Nuvalent, Inc. (NUVL)
Jul 15, 2026 - NUVL was delisted (reason: acquired by GSK)
123.96
+0.02 (0.02%)
Inactive · Last trade price on Jul 14, 2026
Nuvalent Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Nuvalent stock had an average target of $125.13, with a low estimate of $124 and a high estimate of $140.
Price Target: $125.13 (+0.94%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Jul 1, 2026.
Analyst Ratings
The average analyst rating for Nuvalent stock from 17 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 15 | 15 | 16 | 0 |
| Buy | 4 | 4 | 4 | 4 | 4 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 17 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 19 | 19 | 20 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Maintains $124 | Hold | Maintains | $124 | +0.03% | Jul 1, 2026 |
| Bernstein | Bernstein | Hold Downgrades $172 → $124 | Hold | Downgrades | $172 → $124 | +0.03% | Jun 23, 2026 |
| LifeSci Capital | LifeSci Capital | Hold Downgrades $124 | Hold | Downgrades | $124 | +0.03% | Jun 14, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Downgrades $135 → $124 | Hold | Downgrades | $135 → $124 | +0.03% | Jun 11, 2026 |
| Guggenheim | Guggenheim | Hold Downgrades $151 → $124 | Hold | Downgrades | $151 → $124 | +0.03% | Jun 10, 2026 |
Financial Forecast
Revenue This Year
9.42M
Revenue Next Year
184.57M
from 9.42M
Increased by 1,858.40%
EPS This Year
-5.50
from -5.85
EPS Next Year
-4.19
from -5.50
EPS and Forward PE are based on non-GAAP adjusted numbers.